NASDAQ · Biotechnology · USD
Entera Bio Ltd. (ENTX) Stock Analysis
Entera Bio Ltd. (ENTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ENTX Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.99
- Previous Close
- $3.02
- Day's Range
- 2.96–3.20
- 52-Week Range
- 0.91–4.20
- Volume
- 784.60K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.41
Valuation
- Market Cap
- $530.19M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.36
Financials (FY)
- Revenue (FY)
- $42.00K−76.80%
- Net Income (FY)
- −$11.44M
- Shares Outstanding
- 173.83M
- 1-Year Return
- +27.62%
Dividend and dates
- Earnings Date
- November 13, 2026estimated
- Avg Volume
- 1.91M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ENTX closed at $3.05, +27.62% over 1 year.
Entera Bio Ltd. (ENTX) has a market capitalization of $530.19M.
In fiscal 2025, ENTX reported revenue of $42.00K.
ENTX Stock Return by Calendar Year
Entera Bio Ltd. (ENTX) return since Jun 2018: what $10,000 became
- 1 year
- $10,000 $12,762
- +27.62%
- 5 years
- $10,000 $6,674
- −33.26%
- Since Jun 2018
- $10,000 $4,857
- −51.43%
If you had invested $10,000 in Entera Bio Ltd. (ENTX) at the close on June 28, 2018, the earliest close on record here, it would have been worth $4,857 at the close on October 21, 2026: −51.43% in total, −8.32% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +57.22% |
| 2025 | −8.49% |
| 2024 | +253.33% |
| 2023 | −17.81% |
| 2022 | −74.07% |
| 2021 | +160.65% |
| 2020 | −49.53% |
| 2019 | −29.84% |
| 2018 (partial year) | −51.43% |
As of October 21, 2026.
ENTX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $42.00K | −$11.44M | −27,235.7% |
| 2024 | $181.00K | −$9.54M | −5,271.3% |
| 2023 | $0.00 | −$8.89M | — |
| 2022 | $134.00K | −$13.07M | −9,754.5% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $42.00K | $0.00 | −$11.53M | −$11.44M | −27,235.7% |
| 2024 | $181.00K | $9.00K | −$9.59M | −$9.54M | −5,271.3% |
| 2023 | $0.00 | $0.00 | −$8.89M | −$8.89M | — |
| 2022 | $134.00K | $33.00K | −$13.02M | −$13.07M | −9,754.5% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
YahooEntera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meeting
BenzingaEntera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
YahooEntera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
YahooGuggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11
BenzingaCantor Fitzgerald Initiates Coverage On Entera Bio with Overweight Rating
Benzinga
All 14 articles ↓Show fewer ↑
Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9
BenzingaEntera Bio Files Prospectus For Resale Of Up To 134,803,910 Ordinary Shares By Selling Shareholders From July Private Placement
BenzingaEntera Bio (NASDAQ:ENTX) Slides on Wider Q2 Loss Despite FDA Phase 3 Alignment and $275M Cash Raise
ChartMillEntera Announces Second Quarter 2026 Financial Results and Business Updates
YahooEntera Bio Intends To File Ind For EB612 In First Half Of 2027; EB613 Phase 3 Study Initiation Planned For Late 2026, Topline Data Anticipated In Second Half 2028
BenzingaEntera Bio Announces That Post-Hoc Data From Its Phase 2 Clinical Trial Of EB613Has Been Selected For Two Presentations At The American Society For Bone And Mineral Research Annual Meeting
BenzingaEntera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk
BenzingaEntera Bio Enters Into Securities Purchase Agreement For Oversubscribed Private Placement Financing, Expected To Result In Aggregate Gross Proceeds Of ~$275M
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B